mTORC1 acts downstream of the Akt signaling pathway, which is deregulated in approximately 60% of breast cancers and plays critical roles in breast cancer development, progression and resistance to chemotherapeutic drugs [2,3,4,5,6,7,8,9,10,11]. This evidence concerns the gene AKT1 and breast carcinoma.